EquiCord has chosen the Dômes Pharma Group to distribute the world's first injectable stem cell formulation for the treatment of canine osteoarthritis

The independent family group Dômes Pharma has been present in the pharmaceutical industry since 1947 and has 400 employees at 5 sites in France, England and Germany. The Group has been developing, manufacturing and marketing solutions for the health and well-being of pets for more than 75 years and is currently distributed in more than 15 countries.